Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2003-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD003574.PUB2PMID 14974022PMCID PMC8721561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Infliximab (REMICADE) Therapy in the Treatment of Pediatric Crohn's Disease

  2003cited by this paper
• Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot study

  2003cited by this paper
• Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

  2002cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics.

  2001influential reference
• Review article: the clinical role of anti‐TNFα antibody treatment in Crohn's disease

  2000cited by this paper
• Tumor necrosis factor: biology and therapeutic inhibitors.

  2000cited by this paper
• Accuracy of data in abstracts of published research articles.

  1999cited by this paper
• Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

  1999cited by this paper
• Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

  1999cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn's disease.

  1999cited by this paper
• Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

  1999cited by this paper
• Management of Crohn's disease

  1999influential reference
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.

  1997cited by this paper
• Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

  1997cited by this paper
• Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

  1996cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

  1995cited by this paper
• Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

  1995cited by this paper
• The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.

  1995cited by this paper
• Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

  1994cited by this paper
• Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease

  1994cited by this paper
• Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.

  1991cited by this paper
• Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine

  1990cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Targeted therapeutics for IBD unraveling the potential of stimulus-responsive nanoparticles.

  2025cites this paper
• Colorectal cAncer and CrohN's DIsease study (CANDID): An international multicentre retrospective audit

  2025cites this paper
• Comparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study

  2024cites this paper
• Targeting mucosal healing in Crohn’s disease: efficacy of novel pathways and therapeutic targets

  2024cites this paper
• Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline

  2024cites this paper
• Infliximab for medical induction of remission in Crohn's disease

  2023cites this paper
• Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert’s Document Based on a Systematic Literature Review and Extended Delphi Process

  2023cites this paper
• Systematic review: The effectiveness of 6-thioguanine nucleotide-based dose optimisation of thiopurines in the treatment of inflammatory bowel disease

  2023cites this paper
• Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

  2022cites this paper
• Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease

  2022cites this paper
• Effectiveness and safety of methotrexate monotherapy in patients with Crohn’s disease refractory to anti‐TNF‐α: results from the ENEIDA registry

  2021cites this paper
• Microbiota and Drug Response in Inflammatory Bowel Disease

  2021cites this paper
• 6-thioguanine nucleotide monitoring in azathioprine and mercaptopurine monotherapy for the treatment of inflammatory bowel disease

  2021cites this paper
• Investigation of asymptomatic intestinal inflammation in ankylosing spondylitis by fecal calprotectin.

  2021cites this paper
• Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis

  2021cites this paper
• Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn’s disease: a systematic review and meta-analysis

  2021cites this paper
• Selective Targeting of Tumour Necrosis Factor Receptor 1 Induces Stable Protection from Crohn’s-Like Ileitis in TNFΔARE Mice

  2021cites this paper
• ERKRANKUNGEN DER VERDAUUNGSORGANE

  2020cites this paper
• Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients after Initiation of Biologics: A Cohort Study.

  2020cites this paper
• Decreasing major surgical rates for Crohn’s disease in an emerging economy over two decades: Is it due to biologic therapy?

  2020cites this paper
• Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study

  2020cites this paper
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease.

  2019cites this paper
• Effects of anti-TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease.

  2019cites this paper
• Hospitalization trends of the Inflammatory Bowel Disease landscape: A nationwide overview of 16 years.

  2019cites this paper
• Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease

  2019cites this paper
• Crohn's disease.

  2019cites this paper
• Scaling Issues in the Article Entitled “Cytokines in Blood From Septic Patients Interact With Surface-Immobilized Heparin”

  2018cites this paper
• ACG Clinical Guideline: Management of Crohn’s Disease in Adults

  2018cites this paper
• Advances in mesenchymal stromal cell therapy in the management of Crohn’s disease

  2018cites this paper
• Bacillus Calmette Guerin (BCG) Vaccine for Inducing and Maintaining Remission in Crohn's Disease: A Systematic Review

  2018cites this paper
• Scaling Issues in the Article Entitled “Cytokines in Blood From Septic Patients Interact With Surface-Immobilized Heparin”

  2018cites this paper
• Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort

  2018cites this paper
• Evidence-based clinical practice guidelines for inflammatory bowel disease

  2018cites this paper
• Anti-TNF Therapy in Crohn’s Disease

  2018cites this paper
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease

  2018cites this paper
• Mechanisms underlying clinical efficacy of enteral nutrition in inflammatory bowel disease

  2017cites this paper
• Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials

  2017cites this paper
• Infliximab for induction of remission in Crohn's disease

  2017cites this paper
• Studies of TNF-alpha in Alpha-One Antitrypsin Deficient and healthy subjects

  2017cites this paper
• Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort

  2017cites this paper
• Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry

  2017cites this paper
• Systematic review with meta‐analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis

  2017cites this paper
• Psoriasis and inflammatory bowel disease: links and risks

  2016cites this paper
• Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn’s disease

  2016cites this paper
• The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews

  2016cites this paper
• Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease

  2016cites this paper
• Circulating cytokines and cytokine receptors in infliximab treatment failure due to TNF-independent Crohn disease

  2016cites this paper
• Medication management in pediatric chronic illness: Should patient anxiety be considered?

  2016cites this paper
• Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

  2016cites this paper
• Tumour necrosis factor‐α inhibition can stabilize disease in progressive vitiligo

  2015cites this paper
• Type 1 Interferon signalling in human intestinal T cells

  2015influential citation
• Effects of anti-inflammatory therapy on bursting pressure of colonic anastomosis in murine dextran sulfate sodium induced colitis

  2015cites this paper
• The development and assessment of biological treatments for children.

  2015cites this paper
• Crohn’s Disease

  2015cites this paper
• Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

  2015cites this paper
• TNFα Causes Thrombin-Dependent Vagal Neuron Apoptosis in Inflammatory Bowel Disease

  2014cites this paper
• Systematic review with meta‐analysis: malignancies with anti‐tumour necrosis factor‐α therapy in inflammatory bowel disease

  2014cites this paper
• Clinical Study In Crohn ’ s Disease , Anti-TNF-α Treatment Changes the Balance betweenMucosal IL-17 , FOXP 3 , and CD 4 Cells

  2014cites this paper
• Helminth therapy (worms) for induction of remission in inflammatory bowel disease.

  2014cites this paper
• Optimisation de la réponse aux thiopurines par la pharmacogénétique : approches in vitro et cliniques

  2014influential citation
• Time of infliximab therapy initiation and dose escalation in Crohn's disease.

  2014cites this paper
• Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study.

  2014cites this paper
• Tumor Necrosis Factor Suppresses NR5A2 Activity and Intestinal Glucocorticoid Synthesis to Sustain Chronic Colitis

  2014cites this paper
• Therapeutic human monoclonal antibodies in inflammatory diseases.

  2014cites this paper
• Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us?

  2014influential citation
• Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.

  2014cites this paper
• PROBIR NA OPORTUNISTIČKE INFEKCIJE I CIJEPLJENJE PRIJE POČETKA BIOLOŠKE TERAPIJE

  2013cites this paper
• Paediatric inflammatory bowel disease - bench to bedside and nationwide : a detailed analysis of Scottish children with IBD

  2013cites this paper
• The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis

  2013cites this paper
• Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan

  2012cites this paper
• ORAL DELIVERY OF PEPTIDE DRUGS FOR MITIGATION OF CROHN'S DISEASE

  2012cites this paper
• Pharmaka für chronisch-entzündliche Darmerkrankungen

  2012cites this paper
• In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells

  2012cites this paper
• Sargramostim (GM‐CSF) for Induction of Remission in Crohn's Disease: A Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Systematic Review of Randomized Trials

  2012cites this paper
• Changes of the cytokine profile in inflammatory bowel diseases.

  2012cites this paper
• Use of the tumor necrosis factor-blockers for Crohn's disease.

  2012cites this paper
• Calprotectin in ankylosing spondylitis – frequently elevated in feces, but normal in serum

  2012influential citation
• Role of mesenchymal stem cell therapy in Crohn’s disease

  2012cites this paper
• Sargramostim (GM-CSF) for induction of remission in Crohn's disease.

  2011cites this paper
• Antioxidative potential of a combined therapy of anti TNFα and Zn acetate in experimental colitis.

  2011cites this paper
• Spontaneous in vitro IL-6 production in various intestinal segments in patients with inflammatory bowel disease

  2011cites this paper
• Helminths for induction of remission in inflammatory bowel disease

  2011cites this paper
• Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease

  2011cites this paper
• Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

  2011cites this paper
• Cost Effectiveness of Treatments for Inflammatory Bowel Disease

  2011cites this paper
• Mortality in Patients With Septic Shock Correlates With Anti-Inflammatory But not Proinflammatory Immunomodulatory Molecules

  2011cites this paper
• Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.

  2011cites this paper
• An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease

  2011cites this paper
• Effi cacy of Biological Therapies in Infl ammatory Bowel Disease: Systematic Review and Meta-Analysis

  2011cites this paper
• Infliximab to treat Crohn’s disease: an update

  2011cites this paper
• Crohn's disease.

  2011cites this paper
• Pediatric Inflammatory Bowel Disease in the Emergency Department

  2010cites this paper
• Nonelective excisional colorectal surgery in English National Health Service Trusts: a study of outcomes from Hospital Episode Statistics Data between 1996 and 2007.

  2010cites this paper
• Comparison of hemodialysis access flow measurements using flow dilution and in-line dialysance.

  2010cites this paper
• Change in the treatment strategy for pediatric Crohn's disease

  2010cites this paper
• Impact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab

  2010cites this paper
• Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.

  2010cites this paper
• Biologicals in der Gastroenterologie am Beispiel der Anti-TNF-Antikörper

  2010cites this paper
• Efficacy of early treatment with infliximab in pediatric Crohn's disease.

  2010cites this paper